{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095414","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.727366+00:00","generated_at":"2026-05-31T10:07:53.660375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Surrozen Q2 net loss widens to $25.3M on $20.4M warrant loss; cash at $37.8M","bullets":["Cash and cash equivalents $37.8M as of June 30, 2024, up from $27.3M at March 31, 2024.","Net loss $25.3M vs $9.4M in Q2 2023; includes $20.4M loss on issuance of pre-funded warrants and warrants.","R&D expenses decreased to $5.3M from $6.9M YoY, reflecting 2023 restructuring.","Phase 1b trial of SZN-043 for severe alcoholic hepatitis ongoing; proof-of-concept data expected H1 2025.","Boehringer Ingelheim partnership for SZN-413 may trigger $10M milestone if lead candidate nominated in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095414","json":"https://secwatch.observer/filing/0000950170-24-095414.json","markdown":"https://secwatch.observer/filing/0000950170-24-095414.md","text":"https://secwatch.observer/filing/0000950170-24-095414.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024095414/0000950170-24-095414-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017024095414/srzn-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:07:53.660375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}